Short intravenous amphotericin B followed by oral posaconazole using a simple, stratified treatment approach for diabetes or COVID-19 associated rhino-orbito-cerebral mucormycosis: A prospective cohort study.

ABSTRACT:

Objective

To evaluate the efficacy and safety of short-course intravenous amphotericin B followed by sustained release posaconazole tablets for diabetes or COVID-19 associated rhino-orbito-cerebral mucormycosis (ROCM).

Methods

This prospective, pragmatic study included adults with diabetes or COVID-19 associated ROCM. Patients received short (7-14 days) or long (15-28 days) or intravenous antifungal therapy (SHIFT, or LIFT respectively) depending on the presence or absence of brain involvement. All patients received step-down posaconazole tablets, debridement, and glycemic control. The primary outcome was the treatment success at week 14, which was determined by assessing survival and the absence of disease progression through clinical evaluation and nasal endoscopy. Log-bin

SUBMITTER: Manesh A 

PROVIDER: S-EPMC10281032 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature